Shire Expects Intuniv Launch In Mid-’09, As Firm’s ADHD Share Tops 30%
Shire plans to launch its nonstimulant ADHD candidate Intuniv in the second half of 2009, though new studies may be required to gain FDA approval
You may also be interested in...
Trial data could reassure doctors about treating as needed, Lilly says.
Shire is keeping two pending NDAs for new attention deficit hyperactivity disorder treatments in a sort of limbo while it waits to see if the high expectations for the launch of its d-amphetamine prodrug Vyvanse are fulfilled
Shire and manufacturing partner Noven expect an early July launch for Daytrana, the first transdermal patch for the treatment of attention deficit/hyperactivity disorder to receive FDA approval